Udenafil

Udenafil

Systematic (IUPAC) name
3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
Pharmacokinetic data
Biological half-life	7.3–12.1 hours
Identifiers
CAS Number	268203-93-6 N
ATC code	G04BE11 (WHO)
PubChem	CID: 6918523
DrugBank	DB06267 Y
ChemSpider	5293720 Y
UNII	L5IB4XLY36 Y
KEGG	D10027 N
Chemical data
Formula	C25H36N6O4S
Molecular mass	516.657 g/mol
SMILES O=C2\N=C(/Nc1c(nn(c12)C)CCC)c3cc(ccc3OCCC)S(=O)(=O)NCCC4N(C)CCC4
InChI InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32) Y Key:IYFNEFQTYQPVOC-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

The drug udenafil, marketed under the trade name Zydena, is within the PDE5-inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Used, like other PDE5 inhibitors, to treat erectile dysfunction, undenafil was developed by Dong-A Pharmaceutical. With action of fairly rapid onset (peak plasma concentration after 1 to 1.5 hours) yet long duration (plasma half life of 11 to 13 hours), udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use). Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines; in the United States, it has not been approved by the U.S. Food and Drug Administration.